Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.76 |
| ▸ | CNR2 | P34972 | 15/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taranabant SCHEMBL4024243 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL501972 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL17565778 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL29434856 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL304925 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253294 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253304 | 0.86 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL2246652 | 0.85 | CNR1 (0.62) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474367 | 0.81 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474366 | 0.81 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | claimed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | claimed |
| EP-1910375-B1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | MACNEIL TANYA | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | CNR1 6/4885CNR2 10/4885CYP2D6 831/4885 |
| US-20060270650-A1 | Combination therapy for the treatment of obesity | GPR119, GANC, GANAB | CNR1 385/4885CNR2 281/4885CYP2D6 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.